Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2013

View Archived Issues

Report on first-in-man evaluation of a new gene transfer vector for PAD

Novel NURR1-RXR agonist shows promise in animal model of Parkinson's disease

Opicapone useful as levodopa-sparing agent in patients with PD

Celon Pharma identifies novel GSK-3 beta inhibitors for AD

Alligator Bioscience and BioInvent International design new antibodies for cancer

ChronTech reports interim data from phase II ChronVac-C study

Ra Pharmaceuticals collaborates with Merck & Co. on Cyclomimetics

Transfer of rights to exenatide completed in Japan

BIND Therapeutics and Pfizer to develop multiple Accurins

Description of the first reported case of CYP51A1 deficiency in humans

Phase I study begins for ISIS-APOARx

MedImmune acquires AlphaCore Pharma

VivaGel reduces risk of recurrent bacterial vaginosis in phase II study

Positive topline results reported from phase II clinical trial of RSV vaccine

Merck & Co. presents new CMV vaccines

Idenix Pharmaceuticals prepares new agents for HCV infection

Merck Serono and BioMed X enter collaboration to conduct research projects in oncology

Genzyme and Sanofi give update on Evoltra in Japan

EAU strengthens recommendation for Hexvix in bladder cancer

Aspireo reports encouraging results from phase IIa study of somatoprim in acromegaly

AS-1069562 shows promise in animal models of neuropathic pain

Novel gamma-secretase inhibitors disclosed by Merck & Co.

Sage Therapeutics synthesizes novel NMDA receptor modulators

Roche launches new thyroid cancer test

GSK obtains approval for quadrivalent seasonal flu vaccine in Germany and the U.K.

Navidea and Molecular Neuroimaging enroll first subject in NAV-5001 study

GlaxoSmithKline begins phase III study of Benlysta in patients with vasculitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...